Browsing Tag
Zepbound
41 posts
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Can Novo Nordisk catch up—or will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Will payers embrace premium weight loss? Inside the reimbursement risks of next-gen GLP-1s
As GLP‑1 weight‑loss drugs climb toward blockbuster status, insurers and payers face tough choices on coverage. Can premium weight‑loss therapies become mainstream?
Is Eli Lilly the NVIDIA of healthcare? How metabolic drugs became the new AI trade
Discover how Eli Lilly and Company crossed the $1 trillion valuation mark and why its metabolic-health franchise is now being valued like a high-growth tech platform—read more now.
Why Eli Lilly (NYSE: LLY) just joined the $1tn club—and what it means for obesity drug stocks
Find out how Eli Lilly’s weight-loss drug surge has pushed it past a $1 trillion valuation—and what that means for the industry!
Mangoceuticals lands breakthrough partnership with Eli Lilly and Novo Nordisk to deliver low-cost GLP-1 care
Find out how Mangoceuticals’ partnership with Eli Lilly and Novo Nordisk could transform affordable access to Zepbound and Wegovy obesity treatments.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Novo Nordisk eyes FDA approval for high-dose 7.2mg Wegovy after STEP UP trial shows 21% weight loss
Novo Nordisk seeks U.S. approval for 7.2mg Wegovy after 21% average weight loss in trials. Can it outpace Eli Lilly’s Zepbound in the obesity drug race?